8 recruiting. 8 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 8 | Recruiting 8 |
| Phase 1 | 2 | Recruiting 2 |
Follow Personality Disorders: new trials by email Literature Review of Personality Disorders trials Research Report on Personality Disorders
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| SONATA Dose Duration LIFU for OCD ATTN201 - Low Intensity Focused Ultrasound - Obsessive - Compulsive Disorder | Phase 2 | Recruiting | University of Pennsylvania | 20 | 2026-09-15 | 2026-10-21 |
| Ketamine With Dialectical Behavioural Therapy (DBT) for Suicidality in Individuals With Treatment-Resistant Depression and Borderline Personality Disorder (KET-DBT) Ketamine Hydrochloride, Midazolam Hydrochloride, Dialectical Behavioral Therapy (DBT) - Borderline Personality Disorder (BPD), Treatment-Resistant Major Depressive Disorder | Phase 2 | Recruiting | Joshua Rosenblat | 120 | 2026-07-16 | 2026-07-29 |
| A Pilot Trial of One-Day Accelerated TMS and D-cycloserine in Suicidal Patients With Borderline Personality Disorder TMS, D-Cycloserine (DCS) - Borderline Personality Disorder (BPD) | Phase 1 / Phase 2 | Recruiting | Mclean Hospital | 20 | 2026-06-10 | 2026-08-05 |
| MDMA in Borderline Personality Disorder MDMA - Borderline Personality Disorder | Phase 2 | Recruiting | Yale University | 10 | 2025-09-05 | 2026-10-22 |
| Testing Interventions for Borderline Personality Disorder. Sage, Supportive Individual Psychotherapy - Borderline Personality Disorder | Phase 2 | Recruiting | York University | 304 | 2025-09-01 | 2026-04-01 |
| Brain Signal Training to Enhance Affect Down-regulation Amygdala neurofeedback, Sham neurofeedback - Borderline Personality Disorder | Phase 1 / Phase 2 | Recruiting | Central Institute of Mental Health, Mannheim | 164 | 2025-04-23 | 2026-08-17 |
| Early Intervention of Prodromal Schizophrenia Using an NMDA Enhancer NMDAE, Placebo Cap - Prodromal Schizophrenia | Phase 2 | Recruiting | China Medical University Hospital | 48 | 2021-11-01 | 2026-03-24 |
| A Novel Drug for Borderline Personality Disorder NMDA receptor antagonist (active drug), Lactose packed capsule (inert/inactive arm) - Borderline Personality Disorder | Phase 2 | Recruiting | The Alfred | 150 | 2015-01-01 | 2025-08-15 |
Borderline Personality Disorder (6) · Bipolar Disorder (1) · Compulsive Personality Disorder (1) · Depressive Disorder, Major (1) · Depressive Disorder, Treatment-Resistant (1) · Mental Disorders (1) · Schizophrenia (1) · Schizotypal Personality Disorder (1) · Suicidal Ideation (1)
Mental Disorders (7) · Behavior (1) · Behavioral Symptoms (1) · Bipolar and Related Disorders (1) · Depressive Disorder (1) · Mood Disorders (1) · Schizophrenia Spectrum and Other Psychotic Disorders (1) · Self-Injurious Behavior (1) · Suicide (1)
Cycloserine (1) · Ketamine (1) · Midazolam (1) · N-Methyl-3,4-methylenedioxyamphetamine (1)
Central Institute of Mental Health, Mannheim (1) · China Medical University Hospital (1) · Joshua Rosenblat (1) · Mclean Hospital (1) · The Alfred (1) · University of Pennsylvania (1) · Yale University (1) · York University (1)
United States (3) · Canada (2) · Australia (1) · Germany (1) · Taiwan (1)
Christian Paret-Voigt, Dr. (1) · Jayashri Kulkarni AM, MBBS,MPM,FRANZCP,PhD (1) · Jenna M Traynor, PhD (1) · Joshua Brown, MD, PhD (1) · Joshua D. Rosenblat, MD, MSc (1) · Katherine Scangos, MD, PhD (1) · Sarah K Fineberg, MD, PhD (1)